Rupatadine and levocetirizine for seasonal allergic rhinitis: A comparative study of efficacy and safety

Archives of Otolaryngology - Head and Neck Surgery

Volumn 136, Issue 8, 2010, Pages 796-800

  Maiti, Rituparna ^a   Rahman, Jalelur ^a   Jaida, Jyothirmai ^a   Allala, Uma ^a   Palani, Anuradha ^a  

^a Prathima Institute of Medical Sciences   (India)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; LEVOCETIRIZINE; RUPATADINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL COUNT; FEMALE; HAY FEVER; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LEUKOCYTE DIFFERENTIAL COUNT; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS QUALITY OF LIFE QUESTIONNAIRE; TERTIARY HEALTH CARE; TOTAL NASAL SYMPTOM SCORE;

ADOLESCENT; ADULT; CETIRIZINE; CONJUNCTIVITIS, ALLERGIC; CYPROHEPTADINE; EOSINOPHILS; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; IMMUNOGLOBULIN E; LEUKOCYTE COUNT; MALE; QUALITY OF LIFE; RHINITIS, ALLERGIC, SEASONAL; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 77955733884     PISSN: 08864470     EISSN: 1538361X     Source Type: Journal    
DOI: 10.1001/archoto.2010.128     Document Type: Article

References (22)

1. Berger W, Hampel F Jr, Bernstein J, Shah S, Sacks H, Meltzer EO. Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2006;97(3):375-381.
2. Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother. 2006;7(14):1989-2001.
3. Jones N. Allergic rhinitis: aetiology, predisposing and risk factors. Rhinology. 2004;42(2):49-56.
4. Gelfand EW. Inflammatory mediators in allergic rhinitis. J Allergy Clin Immunol. 2004;114(5)(suppl):S135-S138.
5. Broide DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol. 2001;108(2)(suppl):S65-S71.
6. Dykewicz MS, Fineman S, Skoner DP, et al; American Academy of Allergy, Asthma, and Immunology. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 1998;81(5, pt 2):478-518.
7. Ratner PH, Wingertzahn MA, van Bavel JH, Hampel F, Darken PF, Shah T. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;118(5):1142-1148. (Pubitemid 44755181)
8. Greiner AN, Meltzer EO. Pharmacological rationale for treating allergic and non allergic rhinitis. J Allergy Clin Immunol. 2006;118(5):985-998.
9. García Rafanell J. Rupatadine fumarate: antiallergic, histamine and PAF antagonist. Drugs Future. 1996;21(10):1033-1036.
10. Merlos M, Giral M, Balsa D, et al. Rupatadine a new potent, orally active dual antagonist of histamine and platelet activating factor(PAF). J Pharmacol Exp Ther. 1997;280(1):114-121.
11. Giral M, Balsa D, Ferrando R, Merlos M, Garcia-Rafanell J, Forn J. CNS activity profile of rupatadine fumarate, a new dual receptor antagonist of plateletactivating factor and histamine [abstract]. Allergy. 1998;53(suppl 43):131-132.
12. Izquierdo I, Merlos M, García-Rafanell J. Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist: a review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc). 2003;39(6):451-468.
13. Keam SJ, Plosker GL. Rupatadine: a review of its use in the management of allergic disorders. Drugs. 2007;67(3):457-474.
14. Leynadier F, Mees K, Arendt C, Pinelli ME. Efficacy and safety of levocetirizine in seasonal allergic rhinitis. Acta Otorhinolaryngol Belg. 2001;55(4):305-312.
15. Bachert C, Bousquet J, Canonica GW, et al; XPERT Study Group. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol. 2004;114(4):838-844.
16. Ciprandi G, Cirillo I-G, Vizzaccaro A, Tosca MA. Levocetirizine improves nasal obstruction and modulates cytokine pattern inpatients with seasonal allergic rhinitis: a pilot study. Clin Exp Allergy. 2004;34(6):958-964.
17. Bertrand B, Eloy P. Levocetirizine is highly effective in patients with seasonal allergic rhinitis not responding to treatment with other antihistamines: an open multicentre study in Belgium (Xpoll). Abstract (abstract 723) and poster presented at: 19th Congress of the World Allergy Organization; June 26-July 1, 2005; Munich, Germany.
18. Holgate S, Powell R, Jenkins M, Ali O. A treatment for allergic rhinitis: a view on the role of levocetirizine. Curr Med Res Opin. 2005;21(7):1099-1106.
19. Hair PI, Scott LJ. Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies. Drugs. 2006;66(7):973-996.
20. Juniper EF, Guyatt GH, Andersson B, Ferrie PJ. Comparison of powder and aerosolized budesonide in perennial rhinitis: Validation of Rhinitis Quality of Life Questionnaire. Ann Allergy. 1993;70(3):225-230.
21. Izquierdo I, Merlos M, García-Rafanell J. Rupatadine, a new selective histamine H1 receptor and platelet activating factor(PAF) antagonist: a review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc). 2003;39(6):451-468.
22. Barrón S, Ramis I, García-Rafanell J, Merlos M. Inhibitory activity of rupatadine on pro-inflammatory cytokine production, relationship with binding affinity [abstract]. Methods Find Clin Pharmacol. 2005;27(suppl 2):161-162.